RSS

therapeutic candidate

Taiwanese biopharma company, OBI Pharma, has announced that the US Food and Drug Administration (FDA) has granted orphan drug designation for its treatment of hepatocellular carcinoma (HCC), OBI-3424. Read more

News

Catalent Pharma Solutions has signed a multi-year agreement with Grid Therapeutics for the development and manufacture of a lead therapeutic candidate for the treatment of solid tumours. Read more

News